Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Inc <BFRI.OQ> expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Inc BFRI.OQ BFRI.O is expected to show a rise in quarterly revenue when it reports results on August 13 for the period ending June 30 2026
The Woburn Massachusetts-based company is expected to report a 16.3% increase in revenue to $10.5 million from $9.03 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Biofrontera Inc is for a loss of 10 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Biofrontera Inc is $6.00, about 395.9% above its last closing price of $1.21
This summary was machine generated August 11 at 12:36 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales